Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
NCT00971321
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
157
Enrollment
INDUSTRY
Sponsor class
Conditions
Influenza
Interventions
BIOLOGICAL:
Pandemic influenza vaccine GSK2340272A
Sponsor
GlaxoSmithKline